APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ischemia Reperfusion Injury

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Selected research

Market Analysis & Forecast

Global Ischemia Reperfusion Injury Market Analysis and Forecast 2026-2032

21 December 2025190 pages

Choose your research edition.

Industry ResearchIschemia Reperfusion Injury Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Ischemia Reperfusion Injury Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Ischemia Reperfusion Injury Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ischemia Reperfusion Injury Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Ischemia Reperfusion Injury Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Reperfusion injury or reperfusion insult, sometimes called ischemia-reperfusion injury (IRI) or reoxygenation injury, is the tissue damage caused when blood supply returns to tissue (re- + perfusion) after a period of ischemia or lack of oxygen (anoxia or hypoxia). The absence of oxygen and nutrients from blood during the ischemic period creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative stress rather than (or along with) restoration of normal function.

Global Ischemia Reperfusion Injury key players include Angion Biomedica, Catalyst Biosciences, Ischemix Inc, etc.

North America is the largest market, with a share about 50%, followed by Europe, and Japan, both have a share over 20 percent.

Read the full market overview

In terms of product, Phase 2 is the largest segment, with a share about 40%. And in terms of application, the largest application is Kidney Injury, followed by Heart Injury, Intestine Injury, etc.

Report Includes

This report presents an overview of global market for Ischemia Reperfusion Injury, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Ischemia Reperfusion Injury, also provides the revenue of main regions and countries. Of the upcoming market potential for Ischemia Reperfusion Injury, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ischemia Reperfusion Injury revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Ischemia Reperfusion Injury market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Ischemia Reperfusion Injury revenue, projected growth trends, production technology, application and end-user industry.

Ischemia Reperfusion Injury Segment by Company

Angion Biomedica

Catalyst Biosciences

Ischemix Inc

Opsona Therapeutics

Pharming

TheraSource

Bolder Biotechnology

Corline Biomedical

Mifcortx

Balmes Transplantation

NovelMed Therapeutics

Hope Pharmaceuticals

Omeros Corp

Prothix

SBI Pharmaceuticals

Ischemia Reperfusion Injury Segment by Type

Phase 1

Phase 2

Preclinical

Ischemia Reperfusion Injury Segment by Application

Heart Injury

Kidney Injury

Intestine Injury

Other Injury

Ischemia Reperfusion Injury Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ischemia Reperfusion Injury market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ischemia Reperfusion Injury and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ischemia Reperfusion Injury.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Ischemia Reperfusion Injury in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Ischemia Reperfusion Injury company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ischemia Reperfusion Injury revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Ischemia Reperfusion Injury Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Phase 1 Major Player Table 3. Phase 2 Major Player Table 4. Preclinical Major Player Table 5. Global Ischemia Reperfusion Injury Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Heart Injury Major Player Table 7. Kidney Injury Major Player Table 8. Intestine Injury Major Player Table 9. Other Injury Major Player Table 10. Ischemia Reperfusion Injury Industry Trends Table 11. Ischemia Reperfusion Injury Industry Drivers Table 12. Ischemia Reperfusion Injury Industry Opportunities and Challenges Table 13. Ischemia Reperfusion Injury Industry Restraints Table 14. Global Ischemia Reperfusion Injury Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Ischemia Reperfusion Injury Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Ischemia Reperfusion Injury Market Share by Region (2021-2026) Table 17. Global Ischemia Reperfusion Injury Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Ischemia Reperfusion Injury Market Share by Region (2027-2032) Table 19. Global Ischemia Reperfusion Injury Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Ischemia Reperfusion Injury Revenue Market Share by Players (2021-2026) Table 21. Global Ischemia Reperfusion Injury Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Ischemia Reperfusion Injury Key Players Headquarters & Area Served Table 23. Global Ischemia Reperfusion Injury Players, Product Type & Application Table 24. Global Ischemia Reperfusion Injury Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Ischemia Reperfusion Injury by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Ischemia Reperfusion Injury Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Ischemia Reperfusion Injury Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Ischemia Reperfusion Injury Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Ischemia Reperfusion Injury Revenue Market Share by Type (2021-2026) Table 31. Global Ischemia Reperfusion Injury Revenue Market Share by Type (2027-2032) Table 32. Global Ischemia Reperfusion Injury Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Ischemia Reperfusion Injury Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Ischemia Reperfusion Injury Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Ischemia Reperfusion Injury Revenue Market Share by Application (2021-2026) Table 36. Global Ischemia Reperfusion Injury Revenue Market Share by Application (2027-2032) Table 37. Angion Biomedica Company Information Table 38. Angion Biomedica Business Overview Table 39. Angion Biomedica Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Angion Biomedica Ischemia Reperfusion Injury Product Portfolio Table 41. Angion Biomedica Recent Development Table 42. Catalyst Biosciences Company Information Table 43. Catalyst Biosciences Business Overview Table 44. Catalyst Biosciences Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Catalyst Biosciences Ischemia Reperfusion Injury Product Portfolio Table 46. Catalyst Biosciences Recent Development Table 47. Ischemix Inc Company Information Table 48. Ischemix Inc Business Overview Table 49. Ischemix Inc Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Ischemix Inc Ischemia Reperfusion Injury Product Portfolio Table 51. Ischemix Inc Recent Development Table 52. Opsona Therapeutics Company Information Table 53. Opsona Therapeutics Business Overview Table 54. Opsona Therapeutics Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Opsona Therapeutics Ischemia Reperfusion Injury Product Portfolio Table 56. Opsona Therapeutics Recent Development Table 57. Pharming Company Information Table 58. Pharming Business Overview Table 59. Pharming Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Pharming Ischemia Reperfusion Injury Product Portfolio Table 61. Pharming Recent Development Table 62. TheraSource Company Information Table 63. TheraSource Business Overview Table 64. TheraSource Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. TheraSource Ischemia Reperfusion Injury Product Portfolio Table 66. TheraSource Recent Development Table 67. Bolder Biotechnology Company Information Table 68. Bolder Biotechnology Business Overview Table 69. Bolder Biotechnology Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Bolder Biotechnology Ischemia Reperfusion Injury Product Portfolio Table 71. Bolder Biotechnology Recent Development Table 72. Corline Biomedical Company Information Table 73. Corline Biomedical Business Overview Table 74. Corline Biomedical Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Corline Biomedical Ischemia Reperfusion Injury Product Portfolio Table 76. Corline Biomedical Recent Development Table 77. Mifcortx Company Information Table 78. Mifcortx Business Overview Table 79. Mifcortx Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Mifcortx Ischemia Reperfusion Injury Product Portfolio Table 81. Mifcortx Recent Development Table 82. Balmes Transplantation Company Information Table 83. Balmes Transplantation Business Overview Table 84. Balmes Transplantation Ischemia Reperfusion Injury Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Balmes Transplantation Ischemia Reperfusion Injury Product Portfolio Table 86. Balmes Transplantation Recent Development Table 87. NovelMed Therapeutics Company Information Table 88. NovelMed Therapeutics Business Overview Table 89. NovelMed Therapeutics Ischemia Reperfusion Injury Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 90. NovelMed Therapeutics Ischemia Reperfusion Injury Product Portfolio Table 91. NovelMed Therapeutics Recent Development Table 92. Hope Pharmaceuticals Company Information Table 93. Hope Pharmaceuticals Business Overview Table 94. Hope Pharmaceuticals Ischemia Reperfusion Injury Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 95. Hope Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio Table 96. Hope Pharmaceuticals Recent Development Table 97. Omeros Corp Company Information Table 98. Omeros Corp Business Overview Table 99. Omeros Corp Ischemia Reperfusion Injury Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 100. Omeros Corp Ischemia Reperfusion Injury Product Portfolio Table 101. Omeros Corp Recent Development Table 102. Prothix Company Information Table 103. Prothix Business Overview Table 104. Prothix Ischemia Reperfusion Injury Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 105. Prothix Ischemia Reperfusion Injury Product Portfolio Table 106. Prothix Recent Development Table 107. SBI Pharmaceuticals Company Information Table 108. SBI Pharmaceuticals Business Overview Table 109. SBI Pharmaceuticals Ischemia Reperfusion Injury Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 110. SBI Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio Table 111. SBI Pharmaceuticals Recent Development Table 112. North America Ischemia Reperfusion Injury Revenue by Type (2021-2026) & (US$ Million) Table 113. North America Ischemia Reperfusion Injury Revenue by Type (2027-2032) & (US$ Million) Table 114. North America Ischemia Reperfusion Injury Revenue by Application (2021-2026) & (US$ Million) Table 115. North America Ischemia Reperfusion Injury Revenue by Application (2027-2032) & (US$ Million) Table 116. North America Ischemia Reperfusion Injury Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. North America Ischemia Reperfusion Injury Revenue by Country (2021-2026) & (US$ Million) Table 118. North America Ischemia Reperfusion Injury Revenue by Country (US$ Million) & (2027-2032) Table 119. Europe Ischemia Reperfusion Injury Revenue by Type (2021-2026) & (US$ Million) Table 120. Europe Ischemia Reperfusion Injury Revenue by Type (2027-2032) & (US$ Million) Table 121. Europe Ischemia Reperfusion Injury Revenue by Application (2021-2026) & (US$ Million) Table 122. Europe Ischemia Reperfusion Injury Revenue by Application (2027-2032) & (US$ Million) Table 123. Europe Ischemia Reperfusion Injury Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. Europe Ischemia Reperfusion Injury Revenue by Country (2021-2026) & (US$ Million) Table 125. Europe Ischemia Reperfusion Injury Revenue by Country (US$ Million) & (2027-2032) Table 126. China Ischemia Reperfusion Injury Revenue by Type (2021-2026) & (US$ Million) Table 127. China Ischemia Reperfusion Injury Revenue by Type (2027-2032) & (US$ Million) Table 128. China Ischemia Reperfusion Injury Revenue by Application (2021-2026) & (US$ Million) Table 129. China Ischemia Reperfusion Injury Revenue by Application (2027-2032) & (US$ Million) Table 130. Asia Ischemia Reperfusion Injury Revenue by Type (2021-2026) & (US$ Million) Table 131. Asia Ischemia Reperfusion Injury Revenue by Type (2027-2032) & (US$ Million) Table 132. Asia Ischemia Reperfusion Injury Revenue by Application (2021-2026) & (US$ Million) Table 133. Asia Ischemia Reperfusion Injury Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Ischemia Reperfusion Injury Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 135. Asia Ischemia Reperfusion Injury Revenue by Region (US$ Million) & (2021-2026) Table 136. Asia Ischemia Reperfusion Injury Revenue by Region (US$ Million) & (2027-2032) Table 137. SAMEA Ischemia Reperfusion Injury Revenue by Type (2021-2026) & (US$ Million) Table 138. SAMEA Ischemia Reperfusion Injury Revenue by Type (2027-2032) & (US$ Million) Table 139. SAMEA Ischemia Reperfusion Injury Revenue by Application (2021-2026) & (US$ Million) Table 140. SAMEA Ischemia Reperfusion Injury Revenue by Application (2027-2032) & (US$ Million) Table 141. SAMEA Ischemia Reperfusion Injury Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. SAMEA Ischemia Reperfusion Injury Revenue by Country (2021-2026) & (US$ Million) Table 143. SAMEA Ischemia Reperfusion Injury Revenue by Country (US$ Million) & (2027-2032) Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Ischemia Reperfusion Injury Image Figure 2. Global Ischemia Reperfusion Injury Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ischemia Reperfusion Injury Market Size Share 2021 VS 2025 VS 2032 Figure 4. Phase 1 Image Figure 5. Phase 2 Image Figure 6. Preclinical Image Figure 7. Global Ischemia Reperfusion Injury Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Ischemia Reperfusion Injury Market Size Share 2021 VS 2025 VS 2032 Figure 9. Heart Injury Image Figure 10. Kidney Injury Image Figure 11. Intestine Injury Image Figure 12. Other Injury Image Figure 13. Global Ischemia Reperfusion Injury Market Size (US$ Million) & (2021-2032) Figure 14. Global Ischemia Reperfusion Injury Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Ischemia Reperfusion Injury Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Ischemia Reperfusion Injury Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Ischemia Reperfusion Injury Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Ischemia Reperfusion Injury Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Ischemia Reperfusion Injury Revenue Market Share by Type (2021-2032) Figure 21. Global Ischemia Reperfusion Injury Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Ischemia Reperfusion Injury Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Ischemia Reperfusion Injury Revenue Market Share by Application (2021-2032) Figure 24. North America Ischemia Reperfusion Injury Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Ischemia Reperfusion Injury Revenue Share by Type (2021-2032) Figure 26. North America Ischemia Reperfusion Injury Revenue Share by Application (2021-2032) Figure 27. North America Ischemia Reperfusion Injury Revenue Share by Country (2021-2032) Figure 28. United States Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Ischemia Reperfusion Injury Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Ischemia Reperfusion Injury Revenue Share by Type (2021-2032) Figure 33. Europe Ischemia Reperfusion Injury Revenue Share by Application (2021-2032) Figure 34. Europe Ischemia Reperfusion Injury Revenue Share by Country (2021-2032) Figure 35. Germany Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Ischemia Reperfusion Injury Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Ischemia Reperfusion Injury Revenue Share by Type (2021-2032) Figure 45. China Ischemia Reperfusion Injury Revenue Share by Application (2021-2032) Figure 46. Asia Ischemia Reperfusion Injury Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Ischemia Reperfusion Injury Revenue Share by Type (2021-2032) Figure 48. Asia Ischemia Reperfusion Injury Revenue Share by Application (2021-2032) Figure 49. Asia Ischemia Reperfusion Injury Revenue Share by Region (2021-2032) Figure 50. Japan Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Ischemia Reperfusion Injury Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Ischemia Reperfusion Injury Revenue Share by Type (2021-2032) Figure 58. SAMEA Ischemia Reperfusion Injury Revenue Share by Application (2021-2032) Figure 59. SAMEA Ischemia Reperfusion Injury Revenue Share by Country (2021-2032) Figure 60. Brazil Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Ischemia Reperfusion Injury Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Phase 1
  • Phase 2
  • Preclinical
Applications
  • Heart Injury
  • Kidney Injury
  • Intestine Injury
  • Other Injury
Companies covered
  • Angion Biomedica
  • Catalyst Biosciences
  • Ischemix Inc
  • Opsona Therapeutics
  • Pharming
  • TheraSource
  • Bolder Biotechnology
  • Corline Biomedical
  • Mifcortx
  • Balmes Transplantation
  • NovelMed Therapeutics
  • Hope Pharmaceuticals
  • Omeros Corp
  • Prothix
  • SBI Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Ischemia Reperfusion Injury Market by Type
  3. 1.2.1 Global Ischemia Reperfusion Injury Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Phase 1
  5. 1.2.3 Phase 2
  6. 1.2.4 Preclinical
  7. 1.3 Ischemia Reperfusion Injury Market by Application
  8. 1.3.1 Global Ischemia Reperfusion Injury Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Heart Injury
  10. 1.3.3 Kidney Injury
  11. 1.3.4 Intestine Injury
  12. 1.3.5 Other Injury
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Ischemia Reperfusion Injury Market Dynamics
  1. 2.1 Ischemia Reperfusion Injury Industry Trends
  2. 2.2 Ischemia Reperfusion Injury Industry Drivers
  3. 2.3 Ischemia Reperfusion Injury Industry Opportunities and Challenges
  4. 2.4 Ischemia Reperfusion Injury Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Ischemia Reperfusion Injury Market Perspective (2021-2032)
  2. 3.2 Global Ischemia Reperfusion Injury Growth Trends by Region
  3. 3.2.1 Global Ischemia Reperfusion Injury Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Ischemia Reperfusion Injury Market Size by Region (2021-2026)
  5. 3.2.3 Global Ischemia Reperfusion Injury Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Ischemia Reperfusion Injury Revenue by Players
  2. 4.1.1 Global Ischemia Reperfusion Injury Revenue by Players (2021-2026)
  3. 4.1.2 Global Ischemia Reperfusion Injury Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Ischemia Reperfusion Injury Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Ischemia Reperfusion Injury Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Ischemia Reperfusion Injury Key Players Headquarters & Area Served
  7. 4.4 Global Ischemia Reperfusion Injury Players, Product Type & Application
  8. 4.5 Global Ischemia Reperfusion Injury Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Ischemia Reperfusion Injury Market CR5 and HHI
  11. 4.6.3 2025 Ischemia Reperfusion Injury Tier 1, Tier 2, and Tier 3
5 Ischemia Reperfusion Injury Market Size by Type
  1. 5.1 Global Ischemia Reperfusion Injury Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Ischemia Reperfusion Injury Revenue by Type (2021-2032)
  3. 5.3 Global Ischemia Reperfusion Injury Revenue Market Share by Type (2021-2032)
6 Ischemia Reperfusion Injury Market Size by Application
  1. 6.1 Global Ischemia Reperfusion Injury Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Ischemia Reperfusion Injury Revenue by Application (2021-2032)
  3. 6.3 Global Ischemia Reperfusion Injury Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Angion Biomedica
  2. 7.1.1 Angion Biomedica Company Information
  3. 7.1.2 Angion Biomedica Business Overview
  4. 7.1.3 Angion Biomedica Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Angion Biomedica Ischemia Reperfusion Injury Product Portfolio
  6. 7.1.5 Angion Biomedica Recent Developments
  7. 7.2 Catalyst Biosciences
  8. 7.2.1 Catalyst Biosciences Company Information
  9. 7.2.2 Catalyst Biosciences Business Overview
  10. 7.2.3 Catalyst Biosciences Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Catalyst Biosciences Ischemia Reperfusion Injury Product Portfolio
  12. 7.2.5 Catalyst Biosciences Recent Developments
  13. 7.3 Ischemix Inc
  14. 7.3.1 Ischemix Inc Company Information
  15. 7.3.2 Ischemix Inc Business Overview
  16. 7.3.3 Ischemix Inc Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Ischemix Inc Ischemia Reperfusion Injury Product Portfolio
  18. 7.3.5 Ischemix Inc Recent Developments
  19. 7.4 Opsona Therapeutics
  20. 7.4.1 Opsona Therapeutics Company Information
  21. 7.4.2 Opsona Therapeutics Business Overview
  22. 7.4.3 Opsona Therapeutics Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Opsona Therapeutics Ischemia Reperfusion Injury Product Portfolio
  24. 7.4.5 Opsona Therapeutics Recent Developments
  25. 7.5 Pharming
  26. 7.5.1 Pharming Company Information
  27. 7.5.2 Pharming Business Overview
  28. 7.5.3 Pharming Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pharming Ischemia Reperfusion Injury Product Portfolio
  30. 7.5.5 Pharming Recent Developments
  31. 7.6 TheraSource
  32. 7.6.1 TheraSource Company Information
  33. 7.6.2 TheraSource Business Overview
  34. 7.6.3 TheraSource Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  35. 7.6.4 TheraSource Ischemia Reperfusion Injury Product Portfolio
  36. 7.6.5 TheraSource Recent Developments
  37. 7.7 Bolder Biotechnology
  38. 7.7.1 Bolder Biotechnology Company Information
  39. 7.7.2 Bolder Biotechnology Business Overview
  40. 7.7.3 Bolder Biotechnology Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Bolder Biotechnology Ischemia Reperfusion Injury Product Portfolio
  42. 7.7.5 Bolder Biotechnology Recent Developments
  43. 7.8 Corline Biomedical
  44. 7.8.1 Corline Biomedical Company Information
  45. 7.8.2 Corline Biomedical Business Overview
  46. 7.8.3 Corline Biomedical Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Corline Biomedical Ischemia Reperfusion Injury Product Portfolio
  48. 7.8.5 Corline Biomedical Recent Developments
  49. 7.9 Mifcortx
  50. 7.9.1 Mifcortx Company Information
  51. 7.9.2 Mifcortx Business Overview
  52. 7.9.3 Mifcortx Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Mifcortx Ischemia Reperfusion Injury Product Portfolio
  54. 7.9.5 Mifcortx Recent Developments
  55. 7.10 Balmes Transplantation
  56. 7.10.1 Balmes Transplantation Company Information
  57. 7.10.2 Balmes Transplantation Business Overview
  58. 7.10.3 Balmes Transplantation Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Balmes Transplantation Ischemia Reperfusion Injury Product Portfolio
  60. 7.10.5 Balmes Transplantation Recent Developments
  61. 7.11 NovelMed Therapeutics
  62. 7.11.1 NovelMed Therapeutics Company Information
  63. 7.11.2 NovelMed Therapeutics Business Overview
  64. 7.11.3 NovelMed Therapeutics Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  65. 7.11.4 NovelMed Therapeutics Ischemia Reperfusion Injury Product Portfolio
  66. 7.11.5 NovelMed Therapeutics Recent Developments
  67. 7.12 Hope Pharmaceuticals
  68. 7.12.1 Hope Pharmaceuticals Company Information
  69. 7.12.2 Hope Pharmaceuticals Business Overview
  70. 7.12.3 Hope Pharmaceuticals Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Hope Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio
  72. 7.12.5 Hope Pharmaceuticals Recent Developments
  73. 7.13 Omeros Corp
  74. 7.13.1 Omeros Corp Company Information
  75. 7.13.2 Omeros Corp Business Overview
  76. 7.13.3 Omeros Corp Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Omeros Corp Ischemia Reperfusion Injury Product Portfolio
  78. 7.13.5 Omeros Corp Recent Developments
  79. 7.14 Prothix
  80. 7.14.1 Prothix Company Information
  81. 7.14.2 Prothix Business Overview
  82. 7.14.3 Prothix Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Prothix Ischemia Reperfusion Injury Product Portfolio
  84. 7.14.5 Prothix Recent Developments
  85. 7.15 SBI Pharmaceuticals
  86. 7.15.1 SBI Pharmaceuticals Company Information
  87. 7.15.2 SBI Pharmaceuticals Business Overview
  88. 7.15.3 SBI Pharmaceuticals Ischemia Reperfusion Injury Revenue and Gross Margin (2021-2026)
  89. 7.15.4 SBI Pharmaceuticals Ischemia Reperfusion Injury Product Portfolio
  90. 7.15.5 SBI Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Ischemia Reperfusion Injury Revenue (2021-2032)
  2. 8.2 North America Ischemia Reperfusion Injury Revenue by Type (2021-2032)
  3. 8.2.1 North America Ischemia Reperfusion Injury Revenue by Type (2021-2026)
  4. 8.2.2 North America Ischemia Reperfusion Injury Revenue by Type (2027-2032)
  5. 8.3 North America Ischemia Reperfusion Injury Revenue Share by Type (2021-2032)
  6. 8.4 North America Ischemia Reperfusion Injury Revenue by Application (2021-2032)
  7. 8.4.1 North America Ischemia Reperfusion Injury Revenue by Application (2021-2026)
  8. 8.4.2 North America Ischemia Reperfusion Injury Revenue by Application (2027-2032)
  9. 8.5 North America Ischemia Reperfusion Injury Revenue Share by Application (2021-2032)
  10. 8.6 North America Ischemia Reperfusion Injury Revenue by Country
  11. 8.6.1 North America Ischemia Reperfusion Injury Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Ischemia Reperfusion Injury Revenue by Country (2021-2026)
  13. 8.6.3 North America Ischemia Reperfusion Injury Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Ischemia Reperfusion Injury Revenue (2021-2032)
  2. 9.2 Europe Ischemia Reperfusion Injury Revenue by Type (2021-2032)
  3. 9.2.1 Europe Ischemia Reperfusion Injury Revenue by Type (2021-2026)
  4. 9.2.2 Europe Ischemia Reperfusion Injury Revenue by Type (2027-2032)
  5. 9.3 Europe Ischemia Reperfusion Injury Revenue Share by Type (2021-2032)
  6. 9.4 Europe Ischemia Reperfusion Injury Revenue by Application (2021-2032)
  7. 9.4.1 Europe Ischemia Reperfusion Injury Revenue by Application (2021-2026)
  8. 9.4.2 Europe Ischemia Reperfusion Injury Revenue by Application (2027-2032)
  9. 9.5 Europe Ischemia Reperfusion Injury Revenue Share by Application (2021-2032)
  10. 9.6 Europe Ischemia Reperfusion Injury Revenue by Country
  11. 9.6.1 Europe Ischemia Reperfusion Injury Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Ischemia Reperfusion Injury Revenue by Country (2021-2026)
  13. 9.6.3 Europe Ischemia Reperfusion Injury Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Ischemia Reperfusion Injury Revenue (2021-2032)
  2. 10.2 China Ischemia Reperfusion Injury Revenue by Type (2021-2032)
  3. 10.2.1 China Ischemia Reperfusion Injury Revenue by Type (2021-2026)
  4. 10.2.2 China Ischemia Reperfusion Injury Revenue by Type (2027-2032)
  5. 10.3 China Ischemia Reperfusion Injury Revenue Share by Type (2021-2032)
  6. 10.4 China Ischemia Reperfusion Injury Revenue by Application (2021-2032)
  7. 10.4.1 China Ischemia Reperfusion Injury Revenue by Application (2021-2026)
  8. 10.4.2 China Ischemia Reperfusion Injury Revenue by Application (2027-2032)
  9. 10.5 China Ischemia Reperfusion Injury Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Ischemia Reperfusion Injury Revenue (2021-2032)
  2. 11.2 Asia Ischemia Reperfusion Injury Revenue by Type (2021-2032)
  3. 11.2.1 Asia Ischemia Reperfusion Injury Revenue by Type (2021-2026)
  4. 11.2.2 Asia Ischemia Reperfusion Injury Revenue by Type (2027-2032)
  5. 11.3 Asia Ischemia Reperfusion Injury Revenue Share by Type (2021-2032)
  6. 11.4 Asia Ischemia Reperfusion Injury Revenue by Application (2021-2032)
  7. 11.4.1 Asia Ischemia Reperfusion Injury Revenue by Application (2021-2026)
  8. 11.4.2 Asia Ischemia Reperfusion Injury Revenue by Application (2027-2032)
  9. 11.5 Asia Ischemia Reperfusion Injury Revenue Share by Application (2021-2032)
  10. 11.6 Asia Ischemia Reperfusion Injury Revenue by Country
  11. 11.6.1 Asia Ischemia Reperfusion Injury Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Ischemia Reperfusion Injury Revenue by Country (2021-2026)
  13. 11.6.3 Asia Ischemia Reperfusion Injury Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Ischemia Reperfusion Injury Revenue (2021-2032)
  2. 12.2 SAMEA Ischemia Reperfusion Injury Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Ischemia Reperfusion Injury Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Ischemia Reperfusion Injury Revenue by Type (2027-2032)
  5. 12.3 SAMEA Ischemia Reperfusion Injury Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Ischemia Reperfusion Injury Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Ischemia Reperfusion Injury Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Ischemia Reperfusion Injury Revenue by Application (2027-2032)
  9. 12.5 SAMEA Ischemia Reperfusion Injury Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Ischemia Reperfusion Injury Revenue by Country
  11. 12.6.1 SAMEA Ischemia Reperfusion Injury Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Ischemia Reperfusion Injury Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Ischemia Reperfusion Injury Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst